Cencora (NYSE:COR) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Cencora (NYSE:COR) from a buy rating to a hold rating in a research note released on Friday.

COR has been the topic of a number of other research reports. Mizuho boosted their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Robert W. Baird lifted their price target on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. UBS Group raised their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. TD Cowen upped their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Finally, Wells Fargo & Company raised their price objective on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Price Performance

Shares of NYSE COR opened at $368.93 on Friday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The firm has a market cap of $71.53 billion, a price-to-earnings ratio of 37.96, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. Cencora has a 1-year low of $223.92 and a 1-year high of $377.54. The stock has a fifty day simple moving average of $335.71 and a two-hundred day simple moving average of $307.83.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the firm posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts anticipate that Cencora will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the sale, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. This trade represents a 7.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 46,640 shares of company stock worth $14,099,338 over the last ninety days. 10.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cencora

Several hedge funds have recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. IAG Wealth Partners LLC purchased a new position in shares of Cencora in the third quarter worth $30,000. Costello Asset Management INC bought a new stake in Cencora during the 1st quarter valued at $28,000. Cloud Capital Management LLC purchased a new stake in Cencora during the 3rd quarter valued at $31,000. Finally, Caitlin John LLC purchased a new stake in Cencora during the 3rd quarter valued at $31,000. Institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.